| Document |
Document Title |
|
JP2003514524A |
Provided herein are endotheliases and portions, particularly, the protease domains, and nucleic acids that encode the endotheliases. The endotheliases are transmembrane proteases expressed in endothelial cells. The nucleic acids and enco...
|
|
JP2003514545A |
Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will requi...
|
|
JP2003514902A |
The invention relates to compounds of the general formula (I)whereR1 and R2 independently of one another are H, -R6, C3-C8-cycloalkyl, -(CH2)n-R7, -(CH2)n-O-R6, -(CH2)n-NH2, -(CH2)n-NHR6, -(CH2)-N(R6)2, C2-C6-alkenyl or, where appropriat...
|
|
JP2003513050A |
The invention concerns a product comprising at least a NO synthase inhibiting substance associated with at least a phospholipase A2 inhibiting substance, separately or combined, for simultaneous therapeutic use, separately or spread over...
|
|
JP2003096057A |
To provide a pharmaceutical composition which is useful for prevention or treatment of cellular ischemia, ischemic brain, ischemic heart or peripheral ischemia; treatment of chronic neurodegenerative symptoms, and for storage of organs f...
|
|
JP2003512401A |
A non-invasive and non-systemic method for intradermal prevention OR amelioration of pain from a surgically closed wound is disclosed. The method comprises topical delivery of a local anesthetic to an exterior surface of a surgically clo...
|
|
JP2003512420A |
Methods of using 2-amino-3,4-dihydroquinazolines of formula I, or a pharmaceutically tolerable salt thereof, for the treatment or prophylaxis of illnesses caused by ischemic conditions:wherein: R1, R2 and R3 have the meanings indicated i...
|
|
JP2003512455A |
NHE-1 inhibitor crystal of Formula (I), methods of using such NHE-1 inhibitor crystal and pharmaceutical compositions containing such NHE-1 inhibitor crystal. The NHE-1 inhibitor crystal is useful for the reduction of tissue damage resul...
|
|
JP2003512438A |
The invention relates to a medicament comprising 11- beta -hydroxysteroid dehydrogenase inhibitors combined with an antigen in order to improve and optimize tolerance induction.
|
|
JP2003510357A |
A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl, or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. ...
|
|
JP2003510028A |
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for p...
|
|
JP2003073360A |
To provide an 1-diphenylmethylpyrazole derivative as an opioid receptor ligand.This 1-diphenylmethylpyrazole derivative of the general formula (I) (where, R1, R2, R3, R4 and R5 are defined in the Specification) or a pharmaceutically acce...
|
|
JP2003508501A |
Derivatives of antineoplastic agents are prepared. The derivatives are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
|
|
JP2003508502A |
Derivatives of antineoplastic agents are prepared. The derivatives are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
|
|
JP2003508489A |
A promotor of wound healing and an inhibitor of formation of a urethral stricture, particularly following surgical intervention or infection in the area. Specifically, the most preferred compound of the present invention, Halofuginone, c...
|
|
JP2003507091A |
Use of fibrinogen multimers having at least 6 fibrinogen units as an ingredient for a fibrin sealant.
|
|
JP2003507376A |
The invention relates to the compounds of Formula (I), as well as the process for their production and their use as pharmaceutical agents.
|
|
JP2003507092A |
A composition for lubricating a joint is disclosed which comprises a solution or suspension of a phospholipid together with gelatin. The gelatin is preferably succinylated gelatin. The phospholipid, may be phosphatidic acid, phosphatidyl...
|
|
JP3379757B2 |
The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively i...
|
|
JP2003506385A5 |
|
|
JP2003506025A |
Methods are provided for generating nucleic acid ligands of CD40ligand. The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to CD40ligand, and meth...
|
|
JP2003505508A |
The present invention relates to acyclic and cyclic amine derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present inve...
|
|
JP2003505388A |
The present invention relates to certain spirooxindole derivatives of the formula I, and pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are particularly effective in the treatment of chronic pain.
|
|
JP2003504343A |
Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been iden...
|
|
JP2003504159A5 |
|
|
JP2003504056A |
The present invention provides human proteins having hydrophobic domains, DNAs encoding these proteins, expression vectors for these DNAs, transformed eukaryotic cells expressing these DNAs and antibodies directed to these proteins.
|
|
JP2003503367A |
The invention provides a polymeric structure comprising a multifunctional poly(alkylene oxide), such as a poly(ethylene glycol) derivative, covalently cross-linked to a polymer selected from the group consisting of chitosan and conjugate...
|
|
JP2003502286A |
The present invention relates to the use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30), to the use as inhibitors of PARP-homologous enzymes and, in particular, these phthalazine ...
|
|
JP2003502434A |
2-(3-,4-(substituted)-5-alkylthienyl)adenosines and the 5'-uronic acid amide analogues thereof having the following formula:are disclosed herein. Additionally disclosed are medicinal methods of treatment wherein the adenosine A2A agonist...
|
|
JP2003502350A |
The present invention describes the incorporation of liposomal gene constructs directly into a wound to further improve wound repair, or into wound coverage and/or closure materials to enhance the functionality of the material. The prese...
|
|
JP2003501009A |
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for p...
|
|
JP2003501389A |
Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure:or a pharmaceutically acceptable salt thereof, whereinA iswhereinY1 a...
|
|
JP2003501470A |
This invention relates to novel phenyl ureas useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
JP2003500454A |
This invention provides composition comprising a cyclosporin and a carrier medium.
|
|
JP3361523B2 |
The present invention provides an improved means for regulating the immune response, for ameliorating effects of stress, and for avoiding untoward effects of chemotherapy or exposure to irradiation by administration of androstediol (AED)...
|
|
JP2003500022A |
The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
|
|
JP2002544171A |
CCR4 receptor antagonists are described to be suitable to treat and/or prevent septic shock. The antagonists of this invention typically are selected among several classes but preferably are anti-CCR4 antibodies.
|
|
JP2002543764A |
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for p...
|
|
JP2002543137A |
The invention concerns a pharmaceutical composition containing in galenical unit form a combination of active principles with platelet antiaggregating activity consisting of acetylsalicylic acid and clopidogrel hydrogenosulphonate.
|
|
JP2002543108A |
Compositions and methods for systemically minimizing the inflammatory effects of TNF-alpha are disclosed. The compositions include particles of bioactive glass with a particle size less than about 20 mum, alone or in combination with ant...
|
|
JP2002542297A |
The present inventors have surprisingly found that the Mts-1 protein stimulates angiogenesis. In particular, the present inventors have found that Mts-1 transgenic mice developed hemangiomas and stenosis. The present inventors have also ...
|
|
JP2002541804A |
Fifteen secreted human proteins and full-length cDNA sequences encoding the proteins have been identified. The proteins have various potential uses as therapeutics, such as for stimulating blood cell generation in patients receiving canc...
|
|
JP2002541099A |
[Chemical 1] [In the formula, G1 is (C1-C6) Alkyl, (C1-C6) Selected from the group consisting of alkenyl, aryl groups or heteroaryl groups, aryl or heteroaryl is a ring with 5, 6 or 7 atoms and at least one atom of heteroaryl is a sulfur...
|
|
JP2002540769A |
The present invention provides a human apoptosis regulator protein (Aven) and polynucleotides which identify and encode Aven. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic aci...
|
|
JP2002541113A |
Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and ...
|
|
JP2002539076A |
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen but not to native triple helical forms of the collagen. Antagonists of ...
|
|
JP2002539157A |
Angiogenesis is inhibited by the local administration of a pharmaceutical preparation formed from the reaction of hyaluronic acid, carboxymethylcellulose and a carbodiimide. The preparation, which can be in the form of a film or a gel, i...
|
|
JP2002322193A |
To provide an A3 agonist useful for alleviation of tissue ischeamia or tissue damage due to hypoxemia.This A3 agonist has a structure of general formula I. A method for using the A3 agonist and a pharmaceutical composition containing the...
|
|
JP2002537225A |
Novel compounds of formula (I) in which R, R<1> and R<2> have the meaning indicated, and their salts or solvates as glycoprotein IbIX antagonists.
|
|
JP2002316948A |
To obtain a pharmaceutical composition for preventing or treating a disease associated with an excess of IL-12 production.This pharmaceutical composition for preventing and/or treating a disease associated with an excess of IL-12 product...
|
